The present invention provides the S enantiomer of a compound of formula I
1
wherein R.sup.1 represents chloro, trifluoromethyl or trifluoromethoxy,
R.sup.2 represents H or fluoro and R.sup.3 represents a C.sub.2-4alkyl
group as well as pharmaceutically acceptable salts, solvates and prodrugs
thereof, to processes for preparing such compounds, to their the utility
in treating clinical conditions including lipid disorders (dyslipidemias)
whether or not associated with insulin resistance, to methods for their
therapeutic use and to pharmaceutical compositions containing them.
